Berka PRRT Info- Required Info, Dr Richard Baum EMAIL & TREATMENT VIDEO - READ AND STUDY VIDEO IF INTERESTED in BB PRRT!!

The following information is required before Peptide Receptor Radionuclide Therapy (PRRT)- @Bad Berka Clinic in Germany & Dr Baum's address, plus VIDEO of PRRT & GALLIUM 68 SCAN:
Here is some information on requirements for PRRT therapy. As noted, this is serious business. and one should work, and get aligned with, your Oncologist/MD before proceeding with such treatment. It is strongly advised that your MD make the referral to the clinic, or include a letter from her/him agreeing to the therapy.When I went, I had 2 MD's- one a Oncologist, the other a Surgeon, who were advising I undertake this therapy SAP due to my condition. I talked to them both along the way with questions and preparation. It was very helpful to have your MD supportive and advising with such a treatment.

This is the information supplied to me by Bad Berka regarding PRRT treatment requirements and information:

This is what you will need to pre-send to Dr Richard Baum
- all medical (histological and surgical) reports, pathology reports
- recent reports of CT, MRI, sonography, endoscopy
- PET, PET/CT, CT or MRI studies (if performed) on CD (in DICOM format if possible)
- OctreoScan study (original images or study on CD) - this is definitely needed in any case before! Alternatively Ga-68 DOTA-TOC PET study on CD in DICOM format.
- recent blood tests and laboratory values (blood counts (RBC, WBC, platelets), creatinine, urea, liver transaminases)

We will perform at the Zentralklink Bad Berka the following studies:
- somatostatin receptor PET/CT (with Ga-68 DOTA-NOC) for dosimetry purposes.
This PET/CT study will also serve as a control for follow-up (evaluation of therapy response) and is most important.
- GFR measurement using Tc-99m DTPA (if not done within the last 6 weeks)
- kidney scintigraphy using Tc-99m MAG3 for measuring the tubular function (if not done within the last 6 weeks)
- full laboratory tests, including all relevant tumor markers in blood (e.g. chromogranin A, serotonin, gastrin etc.)


The Ga-68 PET/CT and the other tests can be performed also as outpatient (patient must be here in the hospital at 9 hrs a.m.)
Radionulice therapy (PRRT) will be performed as inpatient treatment on our isotope nuclear medicine ward.
Patient can leave the hospital usually on the 3rd day after the treatment in the morning.

CONTACT INFORMATION- EMAIL, ADDRESS AND BAD BERKA VIDEOAddress:
Prof. Dr. med. Richard P. Baum
Dept. of Nuclear Medicine – Center for PET/CT
Zentralklinik Bad Berka
99437 Bad Berka, Germany
Tel: +49 (364) 585-2200 FAX: +49 (364) 585-3515

Email: 1) richard.baum@zentralklinik.de  

2) info@rpbaum.de

Web site: www.zentralklinik-bad-berka.de

Also, below is a video of Dr Baum and the treatment I will be undertaking the the disease itself. It was this video that got me going in the right direction with Dr Baum! Copy and paste it when you have time to watch! It is on the blog entry also!

http://www.youtube.com/user/renalcarcinoidguy#p/f/0/Z0TlXH2dVi8

*THIS VIDEO WAS UPLOADED TO UTUBE COURTESY OF CNETS SINGAPORE AND CARING FOR CARCINOID FOUNDATION

----------------------------------------------------------------------------------------------------------------------------------

ASCO :ARTICLE ON AMERICAN SOCIETY OF CLINICAL ONCOLOGY

J Clin Oncol 26: 2008 (May 20 suppl; abstr 4517)
Citation:
Authors: D. Hörsch, V. Prasad, R. P. Baum-- (ALL Bad Berka Staff)!

Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using
yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides.

Background: Peptide receptor radionuclide therapy (PRRT) is an important new treatment for patients with metastasized neuroendocrine tumors (NET)
resistant to biotherapy or chemotherapy. Yttrium-90 (Y-90)- and/or lutetium-177 (Lu-177) DOTA-TATE (Lu-TATE) have been used alone or in combination over
the last 6 years by us in patients with progressive neuroendocrine tumors. Lu-TATE was predominantly used for small metastases or in patients with impaired
renal or hematological function. Methods: 454 pts (mean age 59.1 years, 248 m, 206f) received a total of 1,303 administrations (mean activity 4.2 GBq, max.
7.5 GBq per cycle, time between courses 3 to 6 months). For kidney protection, 1.5 L of an AA solution (arginine/lysine) were infused IV over 4 hrs. Staging
was performed by CT/MRI and Ga- 68 DOTA-NOC PET-CT or FDG/fluoride PET/CT, blood chemistry and tumor markers (CgA, serotonin). Renal function was
serially determined (Tc-99m MAG3 scan/clearance (TER) and Tc-99m DTPA/GFR measurements). Tumor dosimetry (MIRD/OLINDA) was performed after
PRRT (serial scintigraphies). All data were entered in a structured ACCESS database (284 items/patient). Results: Significant hematological toxicity (mainly
erythrocytopenia, rarely neutropenia, thrombocytopenia) occurred in less than 15% of all patients. End stage renal insuffiency was not observed in any of the
patients with normal kidney function before PRRT. In most patients receiving Lu-TATE alone (n=417 cycles) serum creatinine and TER/GFR did not change.
Tumor response in patients with NETs of non-pancreatic origin and pancreatic NET after a mean follow-up of 2 years: 73/76% stable disease (progressive
disease before), 15/17% had partial and complete remissions and 12/7% PD. 36 patients with advanced disease died of PD. Objective tumor responses
(including improvement of clinical symptoms) were seen in 88/93% of the patients.

Conclusions: Fractionated, individualized PRRT with lower administered
radioactivity given over a longer period of time results in good therapeutic responses in patients with progressive neuroendocrine tumors.

PRRT Information from Rotterdam Clinic and link to the site (Erasmus Medical Center)

Link-----> http://www.prrt.nl/index.php

STUDY RESULTS OF Lutetium-octreotate 177 @ Erasmus

From January 2000 until August 2006 1772 treatments with
lutetium-octreotate were given to a sum of 504 patients. Most
patients had neuroendocrine tumours. A preliminary analysis
in 310 patients with so-called gastroenteropancreatic tumours was
performed after obtaining all results after finishing the treatment.
This showed a decrease in the size of the tumours in 46% of patients, stable
disease in 35% and progression of the tumour despite treatment in 20%.
A significant improvement of quality of life in those patients
with tumour regression was also noted.
The average duration of the effect of therapy was 40 months, calculated from the start of therapy. In addition, there are strong indications that patients
treated with Lutetium-octreotate, on average, survive several years
longer (3-6 years) than patients who did not get this treatment.